文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

免疫功能正常危重患者预防巨细胞病毒再激活的抗病毒治疗安全性与有效性:一项随机临床试验

Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patients: A Randomized Clinical Trial.
PubMed 文献 · JAMA Intern Med · 2017-01-01
一句话结论在CMV血清阳性的机械通气危重患者中,伐更昔洛韦或伐昔洛韦预防可抑制CMV再激活(合并治疗组vs对照组HR 0.14,95%CI 0.04-0.50),但伐昔洛韦组28天死亡率较高(41.2% vs 13.5%)导致该组提前终止。

该单中心、开放标签随机对照试验纳入124例ICU内机械通气至少24小时的CMV血清阳性患者,随机分为伐昔洛韦组(n=34)、低剂量伐更昔洛韦组(n=46)和对照组(n=44),治疗最长28天以抑制病毒再激活。主要终点为28天随访期内血中首次CMV再激活时间。结果显示对照组12例出现病毒再激活,伐更昔洛韦组1例,伐昔洛韦组2例(合并治疗组vs对照组HR 0.14,95%CI 0.04-0.50)。伐昔洛韦组因死亡率较高而提前终止:28天时34例中14例(41.2%)死亡,而终止决定时对照组37例中5例(13.5%)死亡。其他安全性终点组间相似。作者结论认为抗病毒预防可抑制CMV再激活,但鉴于死亡率较高,需大规模试验确定其临床疗效与安全性。

要点

  • 在CMV血清阳性、机械通气≥24小时的危重患者中,伐更昔洛韦或伐昔洛韦预防可降低血中CMV再激活风险(合并治疗组vs对照组HR 0.14,95%CI 0.04-0.50)。
  • 伐昔洛韦组因死亡率较高而提前终止:28天时34例中14例(41.2%)死亡,终止决定时对照组37例中5例(13.5%)死亡。
  • 对照组12例出现病毒再激活,伐更昔洛韦组1例,伐昔洛韦组2例。
  • 其他安全性终点在组间显示相似结果。
  • 作者认为,鉴于死亡率较高,需大规模试验确定CMV抑制的临床疗效与安全性。

适用人群与场景

  • CMV血清阳性、在ICU接受机械通气至少24小时的危重患者。
  • 研究纳入时间为2012年1月1日至2014年1月31日,单中心。
  • 全部患者基线APACHE II评分均值为17.6。

处置流程与药物剂量

  • 伐昔洛韦盐酸盐组(n=34):抗CMV预防,最长28天。
  • 低剂量伐更昔洛韦盐酸盐组(n=46):抗CMV预防,最长28天。
  • 对照组(n=44):无干预。

研究设计与关键结果

  • 研究类型:单中心、开放标签、随机对照临床试验;样本量124例(46例女性,78例男性;平均[SD]年龄56.9[16.9]岁)。
  • 主要终点:28天随访期内血中首次CMV再激活时间;对照组12例再激活,伐更昔洛韦组1例,伐昔洛韦组2例;合并治疗组vs对照组HR 0.14(95%CI 0.04-0.50)。
  • 伐昔洛韦组因死亡率较高而提前终止:28天时34例中14例(41.2%)死亡,终止决定时对照组37例中5例(13.5%)死亡。
  • 其他安全性终点组间显示相似结果。
  • 该试验未以临床终点为效能目标。

证据类型、等级与局限

  • 证据类型:随机对照临床试验(单中心、开放标签)。
  • 作者结论:抗病毒预防(伐昔洛韦或低剂量伐更昔洛韦)可抑制危重患者CMV再激活;但鉴于死亡率较高,需大规模试验确定CMV抑制的临床疗效与安全性。
  • 局限:该试验未以临床终点为效能目标;伐昔洛韦组因死亡率较高而提前终止;作者指出需大规模试验确定临床疗效与安全性。

对床旁实践的改变

  • 在CMV血清阳性、机械通气≥24小时的危重患者中,伐更昔洛韦或伐昔洛韦预防可抑制血中CMV再激活(合并治疗组vs对照组HR 0.14,95%CI 0.04-0.50)。
  • 伐昔洛韦组28天死亡率较高(34例中14例,41.2%),该组因此提前终止;终止决定时对照组37例中5例(13.5%)死亡。
  • 作者认为,鉴于死亡率较高,需大规模试验确定CMV抑制的临床疗效与安全性。

指南或共识出处

  • 临床试验注册号:clinicaltrials.gov NCT01503918。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Latent cytomegalovirus (CMV) infection is present in more than half the adult population, and a viral reactivation (ie, when the virus becomes measurable in body fluids such as blood) can occur in up to one-third of these individuals during episodes of critical illness.

OBJECTIVE: To determine whether antiviral therapy is safe and effective for preventing CMV reactivation in a general population of critically ill patients.

DESIGN, SETTING, AND PARTICIPANTS: A single-center, open-label, randomized, controlled clinical trial recruited 124 CMV-seropositive patients undergoing mechanical ventilation for at least 24 hours in the intensive care unit between January 1, 2012, and January 31, 2014. The mean baseline Acute Physiology and Chronic Health Evaluation II score of all patients was 17.6.

INTERVENTIONS: Patients were randomized to receive anti-CMV prophylaxis with valacyclovir hydrochloride (n = 34) or low-dose valganciclovir hydrochloride (n = 46) for up to 28 days to suppress viral reactivation, or to a control group with no intervention (n = 44).

MAIN OUTCOMES AND MEASURES: Time to first CMV reactivation in blood within the 28-day follow-up period following initiation of the study drug.

RESULTS: Among the 124 patients in the study (46 women and 78 men; mean [SD] age, 56.9 [16.9] years), viral reactivation in the blood occurred in 12 patients in the control group, compared with 1 patient in the valganciclovir group and 2 patients in the valacyclovir group (combined treatment groups vs control: hazard ratio, 0.14; 95% CI 0.04-0.50). Although this trial was not powered to assess clinical end points, the valacyclovir arm was halted prematurely because of higher mortality; 14 of 34 patients (41.2%) had died by 28 days, compared with 5 of 37 (13.5%) patients in the control arm at the point of the decision to halt this arm. Other safety end points showed similar outcomes between groups.

CONCLUSIONS AND RELEVANCE: Antiviral prophylaxis with valacyclovir or low-dose valganciclovir suppresses CMV reactivation in patients with critical illness. However, given the higher mortality, a large-scale trial would be needed to determine the clinical efficacy and safety of CMV suppression.

TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01503918.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Cowley NJ, Owen A, Shiels SC, et al. Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patients: A Randomized Clinical Trial. JAMA Intern Med. 2017. PMID: 28437539. doi:10.1001/jamainternmed.2017.0895

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。